Promoter holding
64.27%
KP
Kekule Pharma Limited - Due diligence report
A 360° intelligence report on Kekule Pharma Limited: trust score, financial health, credit view, compliance, directors, growth and distress …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Kekule Pharma Limited — 360° Intelligence Report
Generated from MCA filings & public records83/100
Trust Score
Low Risk
Kekule Pharma Limited is assessed as Low Risk with a Trust Score of 83/100. Kekule Pharma Limited is an active public limited indian non-government company incorporated in 1984, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 09 Aug 2026 from the latest processed filings. Kekule Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
66/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 50/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (BBB-).
Charges position: 3 open (107.64 cr) · 22 satisfied (109.15 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 9 | 48.0 cr |
| Bank Of Baroda | 3 | 48.0 cr |
| Corporation Bank | 1 | 48.0 cr |
| Standard Chartered Bank | 2 | 48.0 cr |
| Ing Vysya Bank Limited | 3 | 48.0 cr |
| State Bank Of India | 4 | 48.0 cr |
Compliance Score: 66/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (323 disclosure(s)).
- 2 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| NADELLA MADHAVA RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARIMOHAN NAMDEV | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JASWANTHI CHITTABATHINI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KUDARAVALLI DURGARANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRILAKSHMI KUDARAVALLI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KUDARAVALLI RAJA RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SRILAKSHMI KUDARAVALLI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KUDARAVALLI SRIDHAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: KUDARAVALLI DURGARANI (Whole-time director) · SRILAKSHMI KUDARAVALLI (CFO) · KUDARAVALLI RAJA RAO (Whole-time director) · SRILAKSHMI KUDARAVALLI (CFO) · KUDARAVALLI SRIDHAR (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 55 · Distress 90
Growth signals & trust indicators
Asset base grew 1.42 - capacity expansion.
Operating for 41+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
3 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 8.06 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 107.64 cr already registered.
- Compliance gaps should be priced into terms.
Investor view72/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
07 Mar 2024
Director ceased
JASWANTHI CHITTABATHINI
13 Feb 2024
Director appointed
JASWANTHI CHITTABATHINI (Director)
24 Jul 2023
Charge satisfied
Others
Charge satisfied
Bank Of Baroda
29 Mar 2023
Charge created
Others - 38.69 cr
28 Apr 2022
Charge created
Others - 58.95 cr
28 Mar 2022
Charge created
Others - 2.60 cr
16 Feb 2022
Director ceased
KUDARAVALLI RAJA RAO
Director ceased
KUDARAVALLI SRIDHAR
09 Sep 2020
Charge created
Others - 2.77 cr
08 Sep 2020
Charge satisfied
Ing Vysya Bank Limited
21 Aug 2020
Director appointed
HARIMOHAN NAMDEV (Company Secretary)
30 Jul 2020
Charge created
Others - 10.00 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
8 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BBB- from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Wings Pharma | U74899DL1987PTC027499 | New Delhi, Delhi, India |
| Pragati Raw Pharma Private Limited | U52311MH1999PTC120384 | Mumbai, Maharashtra, India |
| Jackson Laboratories | U24230PB1986PTC007168 | Punjab, Punjab, India |
| G.T.Products | U15495TN2002PTC049130 | Chennai, Tamil Nadu, India |
| Pulse Pharmacy | U24239TG1997PTC026151 | Hyderabad, Telangana, India |
| Wardex Pharmaceuticals Private Limited | U51397TN1946PTC005759 | Madras-29, Tamil Nadu, India |
| Ideal Detonators Private Limited | U24292TG1989PTC010513 | Secunderabad, Telangana, India |
| Bakson'S Homoeopathic | U74899DL1989PTC036300 | New Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Kekule Pharma Limited before audits and certifications: compliance score 66/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Kekule Pharma Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 55/100, margin trends, ownership structure and peer set for Kekule Pharma Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Kekule Pharma Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Kekule Pharma Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Kekule Pharma Limited an active company?
Kekule Pharma Limited has MCA status “Active” with a compliance score of 66/100 (Moderate).
Is Kekule Pharma Limited financially healthy?
Kekule Pharma Limited has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.
Should I do business with Kekule Pharma Limited?
Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Kekule Pharma Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 8 active director(s) are on record.
Does Kekule Pharma Limited have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 22 earlier charge(s) stand satisfied.
Is Kekule Pharma Limited up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 66/100 (Moderate).
Is it risky to lend to Kekule Pharma Limited?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
